Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Cahill | M | 37 |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | - |
| Nagesh Mahanthappa | M | 59 |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | 3 years |
| Kanishka Pothula | M | 39 |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | 3 years |
| Thilo Schroeder | M | 42 |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | 3 years |
| Michael Bruce | M | - |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | 4 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dorothy Bailey
- Personal Network
